Program
ensartinib
Also written as “Ensartinib”, “Phase I: X-396 (ensartinib)” and “Phase II: X-396 (ensartinib)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms, led by Betta Pharmaceuticals.
Furthest: phase 3, since Apr 30, 201612 company-led studies, 5 open or runningNext primary completion: Feb 1, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Betta Pharmaceuticals | 125 open or running | phase 3since Apr 30, 2016 | Jun 15, 2012 | Feb 1, 2029phase 2 · NCT07448116 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 15, 2012First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT01625234 · 131 enrolled · United States
- Apr 30, 2016Phase 3 study in Carcinoma, Non-Small-Cell LungNCT02767804 · 290 enrolled · United States, Argentina, Australia and more
- Nov 6, 2016Phase 1 study in Solid TumorNCT02959619 · 48 enrolled · China
- Jul 11, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03215693 · 152 enrolled · China
- Apr 15, 2018Phase 1 study in Lung NeoplasmsNCT03536481 · 74 enrolled · China
- May 16, 2018Phase 2 study in Lung NeoplasmsNCT03608007 · 69 enrolled · China
- Dec 26, 2018Phase 1 study in ALK-POSITIVE NSCLCNCT03804541 · 6 enrolled · China
- May 29, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04415320 · 37 enrolled · China
- Apr 18, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05341583 · 202 planned · China
- Oct 21, 2022Phase 1 study in BioequivalencyNCT05665283 · 32 enrolled · United States
- Jul 1, 2024Phase 1 study in HealthyNCT06492525 · 36 planned · China
- Jan 31, 2026Phase 2 study in Solid Advanced TumorNCT07448116 · 164 planned · China
Ahead
- Feb 1, 2029Primary completion: phase 2 study in Solid Advanced TumorNCT07448116
TargetBeta
ALK →read by rule
“An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), ”NCIt, by rule
“ALK tyrosine kinase receptor inhibitor”ChEMBL 37, by rule
Other programs on ALK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
| lorlatinibrule | Pfizer | phase 4 | 20 |
| gilteritinibrule | Astellas Pharma | phase 3 | 20 |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
| neladalkib | GlaxoSmithKline | phase 3 | 2 |
| Foritinib Succinate | Fosun Pharma | phase 2 | 1 |
| ALK Molecular Glue Degrader TRI-611rule | triana-biomedicines-inc | phase 2 | 1 |
| AQUA07 | Hoffmann-La Roche | phase 1 | 1 |
| SIM0518rule | Simcere Pharmaceutical Group | phase 1 | 1 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07448116Solid Advanced Tumor · China | 2 | Recruiting | Feb 1, 2029 | 164 |
| NCT06492525Healthy · China | 1 | Not yet recruiting | Oct 2024 | 36 |
| NCT05665283Bioequivalency · United States | 1 | Completed | Jan 18, 2023 | 32 |
| NCT05341583Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Jun 1, 2025 | 202 |
| NCT04415320Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Dec 2020 | 37 |
| NCT03804541ALK-POSITIVE NSCLC · China | 1 | UNKNOWN | Jun 2019 | 6 |
| NCT03608007Lung Neoplasms · China | 2 | UNKNOWN | Mar 2020 | 69 |
| NCT03536481Lung Neoplasms · China | 1 | Completed | Jan 9, 2019 | 74 |
| NCT03215693Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | Mar 9, 2020 | 152 |
| NCT02959619Solid Tumor · China | 1 | Completed | Oct 31, 2019 | 48 |
| NCT02767804Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 30, 2025 | 290 |
| NCT01625234Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Sep 17, 2020 | 131 |
How it is read
Names in the registry
- “Ensartinib”, 6 entries
- “Phase I: X-396 (ensartinib)”, 1 entry
- “Phase II: X-396 (ensartinib)”, 1 entry
- “X-396 (ensartinib)”, 1 entry
- “Ensartinib Hydrochloride”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Lung Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.